 | • レポートコード：MRC-3774NR338 • 出版社/出版日：GlobalInfoResearch / 2025年12月 • レポート形態：英語、PDF、約100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療 |
| Single User | ￥528,960 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥793,440 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,057,920 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当社の最新の調査によれば、世界の硝子体内注射剤（Intravitreal Injectable）市場規模は2031年に2,9250百万米ドルに達し、分析期間中に年平均成長率（CAGR）6.9%で成長すると見込まれます。 硝子体内注射剤とは、細い針を用いて眼の硝子体（硝子体腔）へ直接投与される無菌の医薬製剤です。この投与経路により、抗VEGF薬、コルチコステロイド、または抗生物質などの薬剤を眼の後眼部へ標的送達することが可能となり、全身曝露を最小化しつつ高い局所薬物濃度を確保します。硝子体内注射は、加齢黄斑変性（AMD）、糖尿病黄斑浮腫（DME）、網膜静脈閉塞（RVO）、および感染性眼内炎などを含む網膜疾患の治療に一般的に用いられます。 世界の硝子体内注射剤市場は近年、着実な成長を経験しており、主として黄斑浮腫、加齢黄斑変性（AMD）、および網膜静脈閉塞（RVO）といった網膜障害の有病率増加により牽引されています。北米は現在、世界市場を支配しており、50%を超えるシェアを保有し、これに続いて欧州およびアジア太平洋が続き、いずれも40%を超えるシェアを有しています。 薬剤タイプの観点では、抗VEGF（血管内皮増殖因子）療法が最大かつ最も重要な市場セグメントを表し、市場総収益の85%超に寄与しています。これらの薬剤は網膜における異常血管増殖を抑制するのに非常に有効であり、AMDや糖尿病黄斑浮腫（DME）などの疾患における標準治療となっています。コルチコステロイドや抗生物質などの他の治療クラスは、より専門的、または補助的な治療シナリオにおいて通常用いられるため、より小さな役割を担います。 硝子体内注射剤の最大の臨床用途は黄斑浮腫であり、糖尿病および世界的な高齢化人口に関連した発症率の増加が続いています。黄斑変性およびRVOも需要への主要な寄与要因であり、標的型眼科治療の重要性を補強しています。認知の増加、より早期の診断、ならびに眼科医療サービスへのアクセス改善が、先進地域と新興地域の双方において市場拡大をさらに促進しています。 今後、市場は疾患負担の増大と製品革新により、着実に成長すると予想されます。とりわけ、アステラス製薬のような新規参入企業が市場へ参入し始めており、より広範な競争への移行、そして有効性や投与間隔が延長された次世代治療の可能性を示しています。薬物送達システムの進歩、長時間作用型製剤、ならびにバイオシミラーは、市場環境をさらに形成し、新たな成長機会を提供すると見込まれます。 本レポートは、世界の硝子体内注射剤市場に関する詳細かつ包括的な分析です。企業別、地域・国別、薬剤別、疾患別に、定量分析と定性分析の両方が提示されています。市場は常に変化しているため、本レポートでは競争、需給動向、ならびに多くの市場にわたって需要が変化することに寄与する主要要因を検討します。選定された競合企業の企業プロファイルおよび製品例に加え、2025年における選定された一部リーダーの市場シェア推計が提供されます。 主要特徴： ・世界の硝子体内注射剤市場規模および予測（消費額：百万ドル）、2020-2031年 ・地域および国別の世界硝子体内注射剤市場規模および予測（消費額：百万ドル）、2020-2031年 ・薬剤別および疾患別の世界硝子体内注射剤市場規模および予測（消費額：百万ドル）、2020-2031年 ・主要プレイヤーの世界硝子体内注射剤市場シェア（売上：百万ドル）、2020-2025年 本レポートの主目的は以下のとおりです： ・世界および主要国における総市場機会の規模を決定すること ・硝子体内注射剤の成長ポテンシャルを評価すること ・各製品市場および最終用途市場における将来成長を予測すること ・市場に影響を与える競争要因を評価すること 本レポートは、企業概要、売上、粗利益率、製品ポートフォリオ、地理的プレゼンス、および主要な動向というパラメータに基づき、世界の硝子体内注射剤市場における主要プレイヤーをプロファイルしています。本調査の一部として対象となる主要企業には、Regeneron Pharmaceuticals、Bausch & Lomb、Novartis、AbbVie（Allergan）、Alimera Sciences、Roche、Bristol-Myers Squibb、Bayer、Bausch + Lomb、EyePoint Pharmaceuticals等が含まれます。 本レポートはまた、市場の推進要因、抑制要因、機会、新製品の上市または承認に関する主要な洞察も提供します。 市場セグメンテーション 硝子体内注射剤市場は、薬剤別および疾患別に分割されます。2020-2031年の期間について、セグメント間の成長は、薬剤別および疾患別の消費額に関する正確な算出および予測を提供します。この分析は、適格なニッチ市場をターゲットにすることで、貴社の事業拡大に役立ちます。 薬剤別の市場セグメント ・抗VEGF薬 ・コルチコステロイド／ステロイドインプラント ・血栓溶解／酵素剤 ・その他 製剤タイプ別の市場セグメント ・硝子体内注射用溶液 ・硝子体内注射用懸濁液 ・その他 作用持続時間別の市場セグメント ・短時間作用型（4～6週間） ・中時間作用型（8～12週間） ・長時間作用型（6か月超） 疾患別の市場セグメント ・黄斑変性 ・黄斑浮腫 ・ぶどう膜炎 ・網膜静脈閉塞 ・その他 プレイヤー別の市場セグメント（本レポートでカバー） ・Regeneron Pharmaceuticals ・Bausch & Lomb ・Novartis ・AbbVie（Allergan） ・Alimera Sciences ・Roche ・Bristol-Myers Squibb ・Bayer ・Bausch + Lomb ・EyePoint Pharmaceuticals |
According to our latest research, the global Intravitreal Injectable market size will reach USD 29250 million in 2031, growing at a CAGR of 6.9% over the analysis period.
Intravitreal injectables are sterile pharmaceutical formulations administered directly into the vitreous humor of the eye using a fine needle. This route of administration allows for targeted delivery of medications—such as anti-VEGF agents, corticosteroids, or antibiotics—into the posterior segment of the eye, ensuring high local drug concentrations while minimizing systemic exposure. Intravitreal injections are commonly used to treat retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and infectious endophthalmitis.
The global intravitreal injectable market has experienced steady growth in recent years, driven primarily by the rising prevalence of retinal disorders such as macular edema, age-related macular degeneration (AMD), and retinal vein occlusion (RVO). North America currently dominates the global market, holding a share of more than 50%, followed by Europe and Asia-Pacific, each with shares exceeding 40%.
In terms of drug types, anti-VEGF (vascular endothelial growth factor) therapies represent the largest and most significant market segment, contributing to over 85% of total market revenue. These agents are highly effective in inhibiting abnormal blood vessel growth in the retina, making them the standard of care for diseases like AMD and diabetic macular edema (DME). Other therapeutic classes such as corticosteroids and antibiotics play smaller roles, typically in more specialized or adjunctive treatment scenarios.
The largest clinical application of intravitreal injectables is for macular edema, which continues to see a rise in incidence linked to diabetes and aging populations worldwide. Macular degeneration and RVO are also major contributors to demand, reinforcing the importance of targeted ophthalmic treatments. The increase in awareness, earlier diagnosis, and improved accessibility to eye care services are further driving market expansion across both developed and emerging regions.
Looking ahead, the market is expected to grow steadily due to increasing disease burden and product innovation. Notably, new players such as Astellas Pharma have begun entering the market, signaling a shift toward broader competition and possibly next-generation therapies with extended efficacy and dosing intervals. Advances in drug delivery systems, longer-acting formulations, and biosimilars are expected to further shape the landscape and offer new growth opportunities.
This report is a detailed and comprehensive analysis for global Intravitreal Injectable market. Both quantitative and qualitative analyses are presented by company, by region & country, by Drug and by Disease. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Intravitreal Injectable market size and forecasts, in consumption value ($ Million), 2020-2031
Global Intravitreal Injectable market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Intravitreal Injectable market size and forecasts, by Drug and by Disease, in consumption value ($ Million), 2020-2031
Global Intravitreal Injectable market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Intravitreal Injectable
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Intravitreal Injectable market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Regeneron Pharmaceuticals, Bausch & Lomb, Novartis, AbbVie (Allergan), Alimera Sciences, Roche, Bristol-Myers Squibb, Bayer, Bausch + Lomb, EyePoint Pharmaceuticals, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Intravitreal Injectable market is split by Drug and by Disease. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Drug and by Disease. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Drug
Anti-VEGF Agents
Corticosteroids / Steroid Implants
Thrombolytic / Enzymatic Agents
Others
Market segment by Formulation Type
Solution for Intravitreal Injection
Suspension for Intravitreal Injection
Others
Market segment by Duration of Action
Short-acting (4–6 weeks)
Medium-acting (8–12 weeks)
Long-acting (> 6 months)
Market segment by Disease
Macular Degeneration
Macular Edema
Uveitis
Retinal Vein Occlusion
Others
Market segment by players, this report covers
Regeneron Pharmaceuticals
Bausch & Lomb
Novartis
AbbVie (Allergan)
Alimera Sciences
Roche
Bristol-Myers Squibb
Bayer
Bausch + Lomb
EyePoint Pharmaceuticals
1 Market Overview
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Intravitreal Injectable by Drug
1.3.1 Overview: Global Intravitreal Injectable Market Size by Drug: 2020 Versus 2024 Versus 2031
1.3.2 Global Intravitreal Injectable Consumption Value Market Share by Drug in 2024
1.3.3 Anti-VEGF Agents
1.3.4 Corticosteroids / Steroid Implants
1.3.5 Thrombolytic / Enzymatic Agents
1.3.6 Others
1.4 Classification of Intravitreal Injectable by Formulation Type
1.4.1 Overview: Global Intravitreal Injectable Market Size by Formulation Type: 2020 Versus 2024 Versus 2031
1.4.2 Global Intravitreal Injectable Consumption Value Market Share by Formulation Type in 2024
1.4.3 Solution for Intravitreal Injection
1.4.4 Suspension for Intravitreal Injection
1.4.5 Others
1.5 Classification of Intravitreal Injectable by Duration of Action
1.5.1 Overview: Global Intravitreal Injectable Market Size by Duration of Action: 2020 Versus 2024 Versus 2031
1.5.2 Global Intravitreal Injectable Consumption Value Market Share by Duration of Action in 2024
1.5.3 Short-acting (4–6 weeks)
1.5.4 Medium-acting (8–12 weeks)
1.5.5 Long-acting (> 6 months)
1.6 Global Intravitreal Injectable Market by Disease
1.6.1 Overview: Global Intravitreal Injectable Market Size by Disease: 2020 Versus 2024 Versus 2031
1.6.2 Macular Degeneration
1.6.3 Macular Edema
1.6.4 Uveitis
1.6.5 Retinal Vein Occlusion
1.6.6 Others
1.7 Global Intravitreal Injectable Market Size & Forecast
1.8 Global Intravitreal Injectable Market Size and Forecast by Region
1.8.1 Global Intravitreal Injectable Market Size by Region: 2020 VS 2024 VS 2031
1.8.2 Global Intravitreal Injectable Market Size by Region, (2020-2031)
1.8.3 North America Intravitreal Injectable Market Size and Prospect (2020-2031)
1.8.4 Europe Intravitreal Injectable Market Size and Prospect (2020-2031)
1.8.5 Asia-Pacific Intravitreal Injectable Market Size and Prospect (2020-2031)
1.8.6 South America Intravitreal Injectable Market Size and Prospect (2020-2031)
1.8.7 Middle East & Africa Intravitreal Injectable Market Size and Prospect (2020-2031)
2 Company Profiles
2.1 Regeneron Pharmaceuticals
2.1.1 Regeneron Pharmaceuticals Details
2.1.2 Regeneron Pharmaceuticals Major Business
2.1.3 Regeneron Pharmaceuticals Intravitreal Injectable Product and Solutions
2.1.4 Regeneron Pharmaceuticals Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.1.5 Regeneron Pharmaceuticals Recent Developments and Future Plans
2.2 Bausch & Lomb
2.2.1 Bausch & Lomb Details
2.2.2 Bausch & Lomb Major Business
2.2.3 Bausch & Lomb Intravitreal Injectable Product and Solutions
2.2.4 Bausch & Lomb Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.2.5 Bausch & Lomb Recent Developments and Future Plans
2.3 Novartis
2.3.1 Novartis Details
2.3.2 Novartis Major Business
2.3.3 Novartis Intravitreal Injectable Product and Solutions
2.3.4 Novartis Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.3.5 Novartis Recent Developments and Future Plans
2.4 AbbVie (Allergan)
2.4.1 AbbVie (Allergan) Details
2.4.2 AbbVie (Allergan) Major Business
2.4.3 AbbVie (Allergan) Intravitreal Injectable Product and Solutions
2.4.4 AbbVie (Allergan) Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.4.5 AbbVie (Allergan) Recent Developments and Future Plans
2.5 Alimera Sciences
2.5.1 Alimera Sciences Details
2.5.2 Alimera Sciences Major Business
2.5.3 Alimera Sciences Intravitreal Injectable Product and Solutions
2.5.4 Alimera Sciences Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.5.5 Alimera Sciences Recent Developments and Future Plans
2.6 Roche
2.6.1 Roche Details
2.6.2 Roche Major Business
2.6.3 Roche Intravitreal Injectable Product and Solutions
2.6.4 Roche Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.6.5 Roche Recent Developments and Future Plans
2.7 Bristol-Myers Squibb
2.7.1 Bristol-Myers Squibb Details
2.7.2 Bristol-Myers Squibb Major Business
2.7.3 Bristol-Myers Squibb Intravitreal Injectable Product and Solutions
2.7.4 Bristol-Myers Squibb Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.7.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.8 Bayer
2.8.1 Bayer Details
2.8.2 Bayer Major Business
2.8.3 Bayer Intravitreal Injectable Product and Solutions
2.8.4 Bayer Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.8.5 Bayer Recent Developments and Future Plans
2.9 Bausch + Lomb
2.9.1 Bausch + Lomb Details
2.9.2 Bausch + Lomb Major Business
2.9.3 Bausch + Lomb Intravitreal Injectable Product and Solutions
2.9.4 Bausch + Lomb Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.9.5 Bausch + Lomb Recent Developments and Future Plans
2.10 EyePoint Pharmaceuticals
2.10.1 EyePoint Pharmaceuticals Details
2.10.2 EyePoint Pharmaceuticals Major Business
2.10.3 EyePoint Pharmaceuticals Intravitreal Injectable Product and Solutions
2.10.4 EyePoint Pharmaceuticals Intravitreal Injectable Revenue, Gross Margin and Market Share (2020-2025)
2.10.5 EyePoint Pharmaceuticals Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Intravitreal Injectable Revenue and Share by Players (2020-2025)
3.2 Market Share Analysis (2024)
3.2.1 Market Share of Intravitreal Injectable by Company Revenue
3.2.2 Top 3 Intravitreal Injectable Players Market Share in 2024
3.2.3 Top 6 Intravitreal Injectable Players Market Share in 2024
3.3 Intravitreal Injectable Market: Overall Company Footprint Analysis
3.3.1 Intravitreal Injectable Market: Region Footprint
3.3.2 Intravitreal Injectable Market: Company Product Type Footprint
3.3.3 Intravitreal Injectable Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Drug
4.1 Global Intravitreal Injectable Consumption Value and Market Share by Drug (2020-2025)
4.2 Global Intravitreal Injectable Market Forecast by Drug (2026-2031)
5 Market Size Segment by Disease
5.1 Global Intravitreal Injectable Consumption Value Market Share by Disease (2020-2025)
5.2 Global Intravitreal Injectable Market Forecast by Disease (2026-2031)
6 North America
6.1 North America Intravitreal Injectable Consumption Value by Drug (2020-2031)
6.2 North America Intravitreal Injectable Market Size by Disease (2020-2031)
6.3 North America Intravitreal Injectable Market Size by Country
6.3.1 North America Intravitreal Injectable Consumption Value by Country (2020-2031)
6.3.2 United States Intravitreal Injectable Market Size and Forecast (2020-2031)
6.3.3 Canada Intravitreal Injectable Market Size and Forecast (2020-2031)
6.3.4 Mexico Intravitreal Injectable Market Size and Forecast (2020-2031)
7 Europe
7.1 Europe Intravitreal Injectable Consumption Value by Drug (2020-2031)
7.2 Europe Intravitreal Injectable Consumption Value by Disease (2020-2031)
7.3 Europe Intravitreal Injectable Market Size by Country
7.3.1 Europe Intravitreal Injectable Consumption Value by Country (2020-2031)
7.3.2 Germany Intravitreal Injectable Market Size and Forecast (2020-2031)
7.3.3 France Intravitreal Injectable Market Size and Forecast (2020-2031)
7.3.4 United Kingdom Intravitreal Injectable Market Size and Forecast (2020-2031)
7.3.5 Russia Intravitreal Injectable Market Size and Forecast (2020-2031)
7.3.6 Italy Intravitreal Injectable Market Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Intravitreal Injectable Consumption Value by Drug (2020-2031)
8.2 Asia-Pacific Intravitreal Injectable Consumption Value by Disease (2020-2031)
8.3 Asia-Pacific Intravitreal Injectable Market Size by Region
8.3.1 Asia-Pacific Intravitreal Injectable Consumption Value by Region (2020-2031)
8.3.2 China Intravitreal Injectable Market Size and Forecast (2020-2031)
8.3.3 Japan Intravitreal Injectable Market Size and Forecast (2020-2031)
8.3.4 South Korea Intravitreal Injectable Market Size and Forecast (2020-2031)
8.3.5 India Intravitreal Injectable Market Size and Forecast (2020-2031)
8.3.6 Southeast Asia Intravitreal Injectable Market Size and Forecast (2020-2031)
8.3.7 Australia Intravitreal Injectable Market Size and Forecast (2020-2031)
9 South America
9.1 South America Intravitreal Injectable Consumption Value by Drug (2020-2031)
9.2 South America Intravitreal Injectable Consumption Value by Disease (2020-2031)
9.3 South America Intravitreal Injectable Market Size by Country
9.3.1 South America Intravitreal Injectable Consumption Value by Country (2020-2031)
9.3.2 Brazil Intravitreal Injectable Market Size and Forecast (2020-2031)
9.3.3 Argentina Intravitreal Injectable Market Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Intravitreal Injectable Consumption Value by Drug (2020-2031)
10.2 Middle East & Africa Intravitreal Injectable Consumption Value by Disease (2020-2031)
10.3 Middle East & Africa Intravitreal Injectable Market Size by Country
10.3.1 Middle East & Africa Intravitreal Injectable Consumption Value by Country (2020-2031)
10.3.2 Turkey Intravitreal Injectable Market Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Intravitreal Injectable Market Size and Forecast (2020-2031)
10.3.4 UAE Intravitreal Injectable Market Size and Forecast (2020-2031)
11 Market Dynamics
11.1 Intravitreal Injectable Market Drivers
11.2 Intravitreal Injectable Market Restraints
11.3 Intravitreal Injectable Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Intravitreal Injectable Industry Chain
12.2 Intravitreal Injectable Upstream Analysis
12.3 Intravitreal Injectable Midstream Analysis
12.4 Intravitreal Injectable Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
btl
Table of Figures
List of Tables
Table 1. Global Intravitreal Injectable Consumption Value by Drug, (USD Million), 2020 & 2024 & 2031
Table 2. Global Intravitreal Injectable Consumption Value by Formulation Type, (USD Million), 2020 & 2024 & 2031
Table 3. Global Intravitreal Injectable Consumption Value by Duration of Action, (USD Million), 2020 & 2024 & 2031
Table 4. Global Intravitreal Injectable Consumption Value by Disease, (USD Million), 2020 & 2024 & 2031
Table 5. Global Intravitreal Injectable Consumption Value by Region (2020-2025) & (USD Million)
Table 6. Global Intravitreal Injectable Consumption Value by Region (2026-2031) & (USD Million)
Table 7. Regeneron Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 8. Regeneron Pharmaceuticals Major Business
Table 9. Regeneron Pharmaceuticals Intravitreal Injectable Product and Solutions
Table 10. Regeneron Pharmaceuticals Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 11. Regeneron Pharmaceuticals Recent Developments and Future Plans
Table 12. Bausch & Lomb Company Information, Head Office, and Major Competitors
Table 13. Bausch & Lomb Major Business
Table 14. Bausch & Lomb Intravitreal Injectable Product and Solutions
Table 15. Bausch & Lomb Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 16. Bausch & Lomb Recent Developments and Future Plans
Table 17. Novartis Company Information, Head Office, and Major Competitors
Table 18. Novartis Major Business
Table 19. Novartis Intravitreal Injectable Product and Solutions
Table 20. Novartis Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 21. AbbVie (Allergan) Company Information, Head Office, and Major Competitors
Table 22. AbbVie (Allergan) Major Business
Table 23. AbbVie (Allergan) Intravitreal Injectable Product and Solutions
Table 24. AbbVie (Allergan) Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 25. AbbVie (Allergan) Recent Developments and Future Plans
Table 26. Alimera Sciences Company Information, Head Office, and Major Competitors
Table 27. Alimera Sciences Major Business
Table 28. Alimera Sciences Intravitreal Injectable Product and Solutions
Table 29. Alimera Sciences Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 30. Alimera Sciences Recent Developments and Future Plans
Table 31. Roche Company Information, Head Office, and Major Competitors
Table 32. Roche Major Business
Table 33. Roche Intravitreal Injectable Product and Solutions
Table 34. Roche Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 35. Roche Recent Developments and Future Plans
Table 36. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 37. Bristol-Myers Squibb Major Business
Table 38. Bristol-Myers Squibb Intravitreal Injectable Product and Solutions
Table 39. Bristol-Myers Squibb Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 40. Bristol-Myers Squibb Recent Developments and Future Plans
Table 41. Bayer Company Information, Head Office, and Major Competitors
Table 42. Bayer Major Business
Table 43. Bayer Intravitreal Injectable Product and Solutions
Table 44. Bayer Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 45. Bayer Recent Developments and Future Plans
Table 46. Bausch + Lomb Company Information, Head Office, and Major Competitors
Table 47. Bausch + Lomb Major Business
Table 48. Bausch + Lomb Intravitreal Injectable Product and Solutions
Table 49. Bausch + Lomb Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 50. Bausch + Lomb Recent Developments and Future Plans
Table 51. EyePoint Pharmaceuticals Company Information, Head Office, and Major Competitors
Table 52. EyePoint Pharmaceuticals Major Business
Table 53. EyePoint Pharmaceuticals Intravitreal Injectable Product and Solutions
Table 54. EyePoint Pharmaceuticals Intravitreal Injectable Revenue (USD Million), Gross Margin and Market Share (2020-2025)
Table 55. EyePoint Pharmaceuticals Recent Developments and Future Plans
Table 56. Global Intravitreal Injectable Revenue (USD Million) by Players (2020-2025)
Table 57. Global Intravitreal Injectable Revenue Share by Players (2020-2025)
Table 58. Breakdown of Intravitreal Injectable by Company Type (Tier 1, Tier 2, and Tier 3)
Table 59. Market Position of Players in Intravitreal Injectable, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 60. Head Office of Key Intravitreal Injectable Players
Table 61. Intravitreal Injectable Market: Company Product Type Footprint
Table 62. Intravitreal Injectable Market: Company Product Application Footprint
Table 63. Intravitreal Injectable New Market Entrants and Barriers to Market Entry
Table 64. Intravitreal Injectable Mergers, Acquisition, Agreements, and Collaborations
Table 65. Global Intravitreal Injectable Consumption Value (USD Million) by Drug (2020-2025)
Table 66. Global Intravitreal Injectable Consumption Value Share by Drug (2020-2025)
Table 67. Global Intravitreal Injectable Consumption Value Forecast by Drug (2026-2031)
Table 68. Global Intravitreal Injectable Consumption Value by Disease (2020-2025)
Table 69. Global Intravitreal Injectable Consumption Value Forecast by Disease (2026-2031)
Table 70. North America Intravitreal Injectable Consumption Value by Drug (2020-2025) & (USD Million)
Table 71. North America Intravitreal Injectable Consumption Value by Drug (2026-2031) & (USD Million)
Table 72. North America Intravitreal Injectable Consumption Value by Disease (2020-2025) & (USD Million)
Table 73. North America Intravitreal Injectable Consumption Value by Disease (2026-2031) & (USD Million)
Table 74. North America Intravitreal Injectable Consumption Value by Country (2020-2025) & (USD Million)
Table 75. North America Intravitreal Injectable Consumption Value by Country (2026-2031) & (USD Million)
Table 76. Europe Intravitreal Injectable Consumption Value by Drug (2020-2025) & (USD Million)
Table 77. Europe Intravitreal Injectable Consumption Value by Drug (2026-2031) & (USD Million)
Table 78. Europe Intravitreal Injectable Consumption Value by Disease (2020-2025) & (USD Million)
Table 79. Europe Intravitreal Injectable Consumption Value by Disease (2026-2031) & (USD Million)
Table 80. Europe Intravitreal Injectable Consumption Value by Country (2020-2025) & (USD Million)
Table 81. Europe Intravitreal Injectable Consumption Value by Country (2026-2031) & (USD Million)
Table 82. Asia-Pacific Intravitreal Injectable Consumption Value by Drug (2020-2025) & (USD Million)
Table 83. Asia-Pacific Intravitreal Injectable Consumption Value by Drug (2026-2031) & (USD Million)
Table 84. Asia-Pacific Intravitreal Injectable Consumption Value by Disease (2020-2025) & (USD Million)
Table 85. Asia-Pacific Intravitreal Injectable Consumption Value by Disease (2026-2031) & (USD Million)
Table 86. Asia-Pacific Intravitreal Injectable Consumption Value by Region (2020-2025) & (USD Million)
Table 87. Asia-Pacific Intravitreal Injectable Consumption Value by Region (2026-2031) & (USD Million)
Table 88. South America Intravitreal Injectable Consumption Value by Drug (2020-2025) & (USD Million)
Table 89. South America Intravitreal Injectable Consumption Value by Drug (2026-2031) & (USD Million)
Table 90. South America Intravitreal Injectable Consumption Value by Disease (2020-2025) & (USD Million)
Table 91. South America Intravitreal Injectable Consumption Value by Disease (2026-2031) & (USD Million)
Table 92. South America Intravitreal Injectable Consumption Value by Country (2020-2025) & (USD Million)
Table 93. South America Intravitreal Injectable Consumption Value by Country (2026-2031) & (USD Million)
Table 94. Middle East & Africa Intravitreal Injectable Consumption Value by Drug (2020-2025) & (USD Million)
Table 95. Middle East & Africa Intravitreal Injectable Consumption Value by Drug (2026-2031) & (USD Million)
Table 96. Middle East & Africa Intravitreal Injectable Consumption Value by Disease (2020-2025) & (USD Million)
Table 97. Middle East & Africa Intravitreal Injectable Consumption Value by Disease (2026-2031) & (USD Million)
Table 98. Middle East & Africa Intravitreal Injectable Consumption Value by Country (2020-2025) & (USD Million)
Table 99. Middle East & Africa Intravitreal Injectable Consumption Value by Country (2026-2031) & (USD Million)
Table 100. Global Key Players of Intravitreal Injectable Upstream (Raw Materials)
Table 101. Global Intravitreal Injectable Typical Customers
世界のVHH抗体医薬品市場 2025年 According to our (Global Info Research) latest study, the global VHH Antibody Drugs market size was valued at US$ xx million in 2024 and is forecast to a readjusted size of USD xx million by 2031 with a CAGR of xx% during review period. This report is a detailed and comprehensive analysis for global…- インピーダンスベースTEER測定システム市場2025年 According to our (Global Info Research) latest study, the global Impedance-based TEER Measurement System market size was valued at US$ 83 million in 2024 and is forecast to a readjusted size of USD 125 million by 2031 with a CAGR of 6.1% during review period. Impedance-based TEER (Trans Epithelial/E…
- 自律神経失調症の市場規模、疫学、治療薬販売、パイプライン、地域別展望2025-2035 The dysautonomia market reached a value of USD 2.3 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 6.2 Billion by 2035, exhibiting a growth rate (CAGR) of 9.39% during 2025-2035. The dysautonomia market has …
- 世界の自動車金属部品市場2025 The global Automotive Metal Parts market size was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031. Automotive industry metal parts are components or parts that made of metal materials of automotives. Automotive is a…
世界のポリエチレン・ワックス市場2025年 According to our (Global Info Research) latest study, the global Polyethylene Wax market size was valued at US$ 1301 million in 2024 and is forecast to a readjusted size of USD 1594 million by 2031 with a CAGR of 2.9% during review period. In this report, we will assess the current U.S. tariff frame…